Trial Profile
Pharmacokinetic/pharmacodynamic study of sitaoxacin (DU-6859a) in patients with respiratory tract infections mainly caused by caused by S. pneumoniae
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jun 2017
Price :
$35
*
At a glance
- Drugs Sitafloxacin (Primary)
- Indications Bacterial infections; Respiratory tract infections
- Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- 05 Jun 2017 Pooled results of this and another phase III trial assessing clinical dosage, PK/PD parameters and safety of Sitafoloxacin, presented at the ASM Microbe 2017
- 01 Jun 2011 New trial record